Difference between revisions of "Part:BBa K1813005"
 
Line 2: Line 2:
 
<partinfo>BBa_K1813005 short</partinfo>
 
<partinfo>BBa_K1813005 short</partinfo>
  
−
HUMCYPDB1, or more accurately CYP2D6 is a cytochrome p450 enzyme known to metabolize a large range of compounds, through O-demethylation.
+
CYP2D6 is a cytochrome p450 enzyme known to metabolize a large range of compounds, through O-demethylation.
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
Line 17: Line 17:
 
<!-- -->
 
<!-- -->
  
−
<h2> Background of HUMCYPDB1/CYP2D6 </h2>
+
<h2> Background of CYP2D6 </h2>
 
As an active participant in the metabolism of more than 25% of the drugs that we take as humans, it's almost no surprise that it is capable of metabolising imidacloprid as well. It is surprising to note however, that imidacloprid is metabolized through the reduction of the nitro goup on the imidazolidine moiety [1], lowering the toxic effects of imidacloprid. In conjunction with CYP6CM1vQ and CYP6G1, it can minimize the toxicity of imidacloprid prior to spontaneous cleavage between the imidazolidine and nicotic moieties[1].
 
As an active participant in the metabolism of more than 25% of the drugs that we take as humans, it's almost no surprise that it is capable of metabolising imidacloprid as well. It is surprising to note however, that imidacloprid is metabolized through the reduction of the nitro goup on the imidazolidine moiety [1], lowering the toxic effects of imidacloprid. In conjunction with CYP6CM1vQ and CYP6G1, it can minimize the toxicity of imidacloprid prior to spontaneous cleavage between the imidazolidine and nicotic moieties[1].
 
By reducing the nitro moiety, it minimizes toxic effects stemming from the presence of the imidazolidine moiety post cleavage. <br>
 
By reducing the nitro moiety, it minimizes toxic effects stemming from the presence of the imidazolidine moiety post cleavage. <br>

Latest revision as of 00:36, 19 September 2015

CYP2D6

CYP2D6 is a cytochrome p450 enzyme known to metabolize a large range of compounds, through O-demethylation.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 323
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 913
  • 1000
    COMPATIBLE WITH RFC[1000]


Background of CYP2D6

As an active participant in the metabolism of more than 25% of the drugs that we take as humans, it's almost no surprise that it is capable of metabolising imidacloprid as well. It is surprising to note however, that imidacloprid is metabolized through the reduction of the nitro goup on the imidazolidine moiety [1], lowering the toxic effects of imidacloprid. In conjunction with CYP6CM1vQ and CYP6G1, it can minimize the toxicity of imidacloprid prior to spontaneous cleavage between the imidazolidine and nicotic moieties[1]. By reducing the nitro moiety, it minimizes toxic effects stemming from the presence of the imidazolidine moiety post cleavage.

This coding sequence was synthesized and is codon optimized for E. coli. It was originally identified in Homo sapiens, Human Beings [2]. This part is also used in BBa_K1813013.

References

[1] Casida, J. E. (2010). Neonicotinoid metabolism: compounds, substituents, pathways, enzymes, organisms, and relevance. Journal of agricultural and food chemistry, 59(7), 2923-2931.

[2] Gonzalez,F.J., Vilbois,F., Hardwick,J.P., McBride,O.W., Nebert,D.W., Gelboin,H.V. and Meyer,U.A. (1994) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2 (2), 174-179